Shares of Eli Lilly (LLY) are moving lower after President Trump said in the Oval Office that the price of GLP-1 weight loss drugs will come down “pretty fast.” Trump noted his administration is negotiating for lower GLP-1 prices. Shares of Eli Lilly are down 4% to $790.12 in post-market trading while Novo Nordisk (NVO) is down 4% to $54.01.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Trump says cost of GLP-1 drugs to come down ‘pretty fast’, Bloomberg says
- Eli Lilly and Cipla’s Diabetes Study: A Market Game Changer?
- Eli Lilly’s Latest Study on Obesity Treatment: A Promising Update
- Novo Nordisk (NVO) Starts Cutting Jobs in the United States
- Nektar litigation hearing against Lilly delayed, says B. Riley